SCHEMBL7200653

SCHEMBL7200653

COc1cc(Cl)c(C(=O)c2ccc(Nc3ccccc3N)cc2Cl)c(Cl)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 18/20 0.71
MAPK13 O15264 14/20 0.71
MAPK12 P53778 14/20 0.71
MAPK11 Q15759 14/20 0.71
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
THRB P10828 1/20 0.50
HTT P42858 1/20 0.50
RECQL P46063 1/20 0.50
MMP14 P50281 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7196493 0.91 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL7192115 0.91 MAPK14 (0.77) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL6654479 0.83 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL7194247 0.83 MAPK13 (0.67) MAPK14MAPK13MAPK12MAPK11MEN1
SCHEMBL6652753 0.82 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11GAA
SCHEMBL7198670 0.81 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL7196010 0.81 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6654823 0.79 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11GAA
SCHEMBL5989531 0.79 MAPK14 (0.78) MAPK14MAPK13MAPK12MAPK11GAA
SCHEMBL2201099 0.79 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1202954-B1 NOVEL AMINOBENZOPHENONES LEO PHARMA AS (DK) 2003-10-01 EP claimed
US-6624199-B1 Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) 2003-09-23 US claimed
US-20020165286-A1 Dermal anti-inflammatory composition LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-11-07 US claimed
EP-1202954-A1 NOVEL AMINOBENZOPHENONES LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-05-08 EP claimed
WO-2001005744-A1 NOVEL AMINOBENZOPHENONES Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) 2001-01-25 WO claimed
EP-1202954-B1 NOVEL AMINOBENZOPHENONES LEO PHARMA AS (DK) 2003-10-01 EP disclosed
US-6624199-B1 Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) 2003-09-23 US disclosed
US-20020165286-A1 Dermal anti-inflammatory composition LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-11-07 US disclosed
WO-2002045752-A2 DERMAL ANTI-INFLAMMATORY COMPOSITION LEO PHARMA A/S (DK) 2002-06-13 WO disclosed
EP-1202954-A1 NOVEL AMINOBENZOPHENONES LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-05-08 EP disclosed
WO-2001005744-A1 NOVEL AMINOBENZOPHENONES Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165286-A1 Dermal anti-inflammatory composition CUTA, IL1B, LRBA MAPK14 644/4885MAPK13 1521/4885MAPK12 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.